Format

Send to

Choose Destination
PLoS One. 2019 Dec 9;14(12):e0225729. doi: 10.1371/journal.pone.0225729. eCollection 2019.

Evaluation of upconverting nanoparticles towards heart theranostics.

Author information

1
Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR1048, Université de Toulouse, France.
2
Groupe de Recherche en Pharmacologie Animale du Québec (GREPAQ), Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec, Canada.
3
CEMES-CNRS, Université de Toulouse, CNRS, France.
4
Service Microchirurgie, Centre Régional d'Exploration Fonctionnelle et Ressources Expérimentales (CREFRE- US06, Rangueil).
5
Fédération des services de cardiologie, hôpital Rangueil.
6
Laboratoire des IMRCP, Université de Toulouse, CNRS UMR 5623, Université Toulouse III-Paul Sabatier.
7
CHROMALYS SAS, France.
8
Service de Pharmacologie Clinique, CHU de Toulouse, Université de Toulouse, France.
9
Département de Neurologie et Institut des Neurosciences, Université de Toulouse, France.

Abstract

Restricted and controlled drug delivery to the heart remains a challenge giving frequent off-target effects as well as limited retention of drugs in the heart. There is a need to develop and optimize tools to allow for improved design of drug candidates for treatment of heart diseases. Over the last decade, novel drug platforms and nanomaterials were designed to confine bioactive materials to the heart. Yet, the research remains in its infancy, not only in the development of tools but also in the understanding of effects of these materials on cardiac function and tissue integrity. Upconverting nanoparticles are nanomaterials that recently accelerated interest in theranostic nanomedicine technologies. Their unique photophysical properties allow for sensitive in vivo imaging that can be combined with spatio-temporal control for targeted release of encapsulated drugs. Here we synthesized upconverting NaYF4:Yb,Tm nanoparticles and show for the first time their innocuity in the heart, when injected in the myocardium or in the pericardial space in mice. Nanoparticle retention and upconversion in the cardiac region did not alter heart rate variability, nor cardiac function as determined over a 15-day time course ensuing the sole injection. Altogether, our nanoparticles show innocuity primarily in the pericardial region and can be safely used for controlled spatiotemporal drug delivery. Our results support the use of upconverting nanoparticles as potential theranostics tools overcoming some of the key limitations associated with conventional experimental cardiology.

PMID:
31815963
PMCID:
PMC6901177
DOI:
10.1371/journal.pone.0225729
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center